Corline Biomedical projects 30 MSEK in 2027 revenue and reaffirms its long-term growth strategy, citing a fully funded business plan and significant potential from its Kardium partnership and broader development portfolio.
Corline issued a 2027 revenue guidance of 30 MSEK and reiterated the Kardium agreement's potential of about 2 billion SEK total, with annual potential of about 200 MSEK at full ramp and EBIT margin above 60%. The board also states the business plan is fully funded, removing near-term capital raise concerns. These concrete targets support a higher equity value.
30 MSEK, based on customer forecasts and contractual commitments.
About 2 billion SEK over the contract period, with an annual potential of about 200 MSEK at full commercial ramp-up.
Corline Biomedical has released its 2027 revenue guidance of 30 MSEK, underpinned by strong customer forecasts and contractual commitments. The company confirmed its business plan is fully funded, anticipating positive EBITDA by 2027, and reiterated the 2 billion SEK long-term potential of its Kardium partnership.
Corline projects 30 MSEK in revenue for 2027, based on customer forecasts and contractual commitments within its commercial partnerships.
The partnership is estimated to generate approximately 2 billion SEK over the contract period, with an annual potential of 200 MSEK once full commercial ramp-up is achieved.